{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:49:22Z","timestamp":1790693362285,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of first-line targeted synthetic DMARDs (tsDMARDs) in patients with RA and chronic kidney disease (CKD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed. The patients were categorized by kidney function and tsDMARD modality. The primary outcome was the 24-month drug retention rate, and the secondary outcomes were changes in the Disease Activity Score 28-CRP (DAS28-CRP) level, prednisolone dosage and reasons for discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 24-month drug retention rates according to the estimated glomerular filtration rate (eGFR) (\u226560%, 30\u201360% or &amp;lt;30\u2009ml\/min\/1.73 m2) were as follows: all tsDMARDs (46.0%, 44.1%, 47.1%), tofacitinib (55.9%, 53.3%, 66.7%), baricitinib (64.2%, 42.0%) and peficitinib (36.4%, 44.1%, 40.0%). Even in groups with lower kidney function, the drug retention rate was maintained (adjusted hazard ratio was 1.14 [95% confidence interval, 0.81\u20131.62], P = 0.45). Patients had a decreased DAS28-CRP (P\u2009&amp;lt;\u20090.01) and a reduced prednisolone dosage (P\u2009&amp;lt;\u20090.01) over the six-month period following tsDMARD initiation. The incidence of herpes zoster and deep vein thrombosis (DVT) was higher in the group with an eGFR &amp;lt;30\u2009ml\/min\/1.73 m2, but not statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD; however, clinicians should consider the potential for herpes zoster and DVT in patients with eGFR &amp;lt;30\u2009ml\/min\/1.73 m2.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf050","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:34:50Z","timestamp":1737822890000},"page":"3396-3404","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-9747","authenticated-orcid":false,"given":"Yusuke","family":"Yoshimura","sequence":"first","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-9691","authenticated-orcid":false,"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-1067","authenticated-orcid":false,"given":"Hiroki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-3291","authenticated-orcid":false,"given":"Yuki","family":"Oba","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0825-2512","authenticated-orcid":false,"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kishioka","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Tanimizu","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kamido","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikuma","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiho","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7326-4988","authenticated-orcid":false,"given":"Akinari","family":"Sekine","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-5183","authenticated-orcid":false,"given":"Takehiko","family":"Wada","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-8203","authenticated-orcid":false,"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-4094","authenticated-orcid":false,"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital , Tokyo,","place":["Japan"]},{"name":"Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"2025052703540229000_keaf050-B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025052703540229000_keaf050-B2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/ard-2024-225914","article-title":"Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease","volume":"83","author":"Yoshimura","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703540229000_keaf050-B3","doi-asserted-by":"publisher","first-page":"e002700","DOI":"10.1136\/rmdopen-2022-002700","article-title":"Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study","volume":"8","author":"Tidblad","year":"2022","journal-title":"RMD Open"},{"key":"2025052703540229000_keaf050-B4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025052703540229000_keaf050-B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2025052703540229000_keaf050-B6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025052703540229000_keaf050-B7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025052703540229000_keaf050-B8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a Janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2025052703540229000_keaf050-B9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2025052703540229000_keaf050-B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40261-019-00873-7","article-title":"Pharmacokinetics and safety of a single oral dose of peficitinib (ASP015K) in Japanese subjects with normal and impaired renal function","volume":"40","author":"Miyatake","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2025052703540229000_keaf050-B11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2025052703540229000_keaf050-B12","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bcp.13726","article-title":"Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor","volume":"84","author":"Namour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025052703540229000_keaf050-B13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025052703540229000_keaf050-B14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025052703540229000_keaf050-B15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.ki.5002273","article-title":"Chronic kidney disease management in the United Kingdom: NEOERICA project results","volume":"72","author":"Stevens","year":"2007","journal-title":"Kidney Int"},{"key":"2025052703540229000_keaf050-B16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","article-title":"Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms","volume":"15","author":"Wattanakit","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"2025052703540229000_keaf050-B17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.ajkd.2012.03.018","article-title":"Risk of herpes zoster in CKD: a matched-cohort study based on administrative data","volume":"60","author":"Wu","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025052703540229000_keaf050-B18","doi-asserted-by":"crossref","first-page":"792877","DOI":"10.3389\/fphar.2021.792877","article-title":"Potential adverse events reported with the Janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025052703540229000_keaf050-B19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025052703540229000_keaf050-B20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nature Rev Rheumatol"},{"key":"2025052703540229000_keaf050-B21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/1346-8138.15214","article-title":"Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014","volume":"47","author":"Imafuku","year":"2020","journal-title":"J Dermatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf050\/61625741\/keaf050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3396\/61625741\/keaf050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3396\/61625741\/keaf050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:54:17Z","timestamp":1748332457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3396\/7979251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,25]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf050","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,25]]}}}